Literature DB >> 9886872

Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels.

A H Danser1, F H Derkx, H W Hense, X Jeunemaître, G A Riegger, H Schunkert.   

Abstract

OBJECTIVE: The angiotensinogen T235 allele is associated with elevated plasma angiotensinogen levels whereas the angiotensin-converting enzyme (ACE) deletion (D) allele is associated with elevated ACE activity. It remains unclear, however, whether these genetically mediated elevations of angiotensinogen and ACE levels are functionally relevant Given that the renin-angiotensin system is subject to renin feedback regulation, we specifically investigated the associations between the angiotensinogen T235 allele and the ACE D allele with plasma renin and prorenin levels. DESIGN AND METHODS: Plasma levels of renin, prorenin, angiotensinogen, ACE and aldosterone, as well as angiotensinogen and ACE genotypes were determined in 228 men and 168 women (age 52-65 years), who had participated in a population survey in southern Germany. Subjects taking antihypertensive drugs or oestrogen replacement therapy were excluded.
RESULTS: We corroborated previous findings demonstrating associations between the T235M polymorphism and plasma angiotensinogen levels (P < 0.05) and between the ACE I/D polymorphism and plasma ACE (P < 0.01). After adjustment for sex, age and blood pressure, the T235 allele of the angiotensinogen gene was also related to lower plasma prorenin (P < 0.03) and renin (P < 0.01) levels, but not to plasma ACE and aldosterone. By contrast, the ACE I/D polymorphism was not related to components of the system other than plasma ACE.
CONCLUSIONS: The angiotensinogen T235 allele is associated with decreased renin levels. This finding may point to a mechanism that counteracts the genetic elevation of angiotensinogen plasma levels and, thus, the plasmatic angiotensin II-generating pathway in subjects carrying the angiotensinogen T235 allele. These results may help to explain discrepant findings regarding associations between this allele and cardiovascular disorders. Furthermore, the presumed feedback downregulation of renin levels supports the importance of angiotensinogen as a determinant of angiotensin II generation. Finally, no evidence was found suggesting that the ACE D allele affects components of the circulating renin-angiotensin system other than plasma ACE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886872     DOI: 10.1097/00004872-199816121-00005

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene.

Authors:  J R Ortlepp; H P Vosberg; S Reith; F Ohme; N G Mahon; D Schröder; H G Klues; P Hanrath; W J McKenna
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 2.  The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure.

Authors:  Omer Aras; Steven A Messina; Jamshid Shirani; William C Eckelman; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

3.  Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.

Authors:  Kye-Min Kim; Michael D Murray; Wanzhu Tu; Jason Robarge; Yan Ding; D Craig Brater; David A Flockhart
Journal:  Eur J Clin Pharmacol       Date:  2012-04-29       Impact factor: 2.953

Review 4.  New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies.

Authors:  G A MacGowan; D M McNamara
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

Review 5.  Genomic variation and neurohormonal intervention in heart failure.

Authors:  Dennis M McNamara
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

6.  The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy.

Authors:  Iris C R M Kolder; Michelle Michels; Imke Christiaans; Folkert J Ten Cate; Danielle Majoor-Krakauer; Alexander H J Danser; Robert H Lekanne Deprez; Michael W T Tanck; Arthur A M Wilde; Connie R Bezzina; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2012-05-09       Impact factor: 4.246

Review 7.  [Role of the angiotensinogen gene for essential hypertension].

Authors:  E Brand; J Ringel; A M Sharma
Journal:  Herz       Date:  2000-02       Impact factor: 1.740

8.  Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background.

Authors:  Marzia Rigolli; Mariantonietta Cicoira; Corinna Bergamini; Andrea Chiampan; Andrea Rossi; Corrado Vassanelli
Journal:  Cardiol Res Pract       Date:  2011-01-05       Impact factor: 1.866

Review 9.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Authors:  Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.